Actin-Aggregating Cucurbitacins from *Physocarpus capitatus*

Katherine N. Maloney,[†] Masaki Fujita,[†] Ulrike S. Eggert,[†,§] Frank C. Schroeder,[†] Christine M. Field,[‡] Timothy J. Mitchison,[‡] and Jon Clardy*,[†]

Department of Biological Chemistry and Molecular Pharmacology, and Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, and Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115

Received August 19, 2008

Bioassay-guided fractionation of *Physocarpus capitatus* yielded two new cucurbitacins (**3** and **4**) along with the known cucurbitacin F (**1**) and dihydrocucurbitacin F (**2**). Preliminary mechanism of action studies indicate that the cucurbitacins cause actin aggregates and inhibit cell division.

Natural products have provided the vast majority of small-molecule probes for studying the cell cycle and the cytoskeleton,[1,2] as illustrated by the tubulin-interactive agents Taxol, vincristine, and halichondrin B.[3] Natural product probes of actin include the cytochalasins and latrunculin B, which inhibit actin polymerization, and jasplakinolide, which induces actin polymerization. These natural products have greatly facilitated our understanding of the role of actin in several fundamental processes. In a classic example from the 1970s, the actin binder cytochalasin was used to show that actin plays a key role in cytokinesis, the final step of cell division. Researchers observed that cytochalasin inhibited multiple processes such as cell migration, cell ruffling, and division, and they reasoned that a single protein, which turned out to be actin, was involved in these processes. Treatment of cells with cytochalasin resulted in inhibition of cellular division (cytokinesis), but not nuclear division (mitosis), providing the first evidence that the two processes can be decoupled from each other. Researchers then went on to show that the target of cytochalasin was actin and that it was a key protein in cytokinesis.[4] Given the demonstrated value of natural products in studying the cytoskeleton, the discovery of additional small-molecule probes should prove useful.

In an effort to find inhibitors of cytokinesis, approximately 51 000 small molecules—belonging to libraries of "drug-like" compounds, combinatorial libraries, and crude natural product extract libraries provided by the NCI—were screened in a high-throughput imaging assay.[5] In this screen, *Drosophila* Kc_{167} cells were exposed to small molecules, allowed to undergo a complete cell cycle, fixed, and stained with tetramethylrhodamine-NHS ester (to visualize the cytoplasm) and Hoechst dye (to visualize the DNA). Stained cells were imaged using automated fluorescence microscopy, and cells with multiple nuclei (that is, cells capable of undergoing mitosis but incapable of cytokinesis) were scored by a combination of automated image analysis and visual inspection. This cell-based approach allowed for the possibility of discovering unknown targets, and molecules that hit should also have an improved chance of providing drug leads, since they have already demonstrated cell penetration and effectiveness in vivo.[6] Interestingly, although natural products represented only 5% of the total compounds screened, they accounted for 25% of the hits.

A crude extract of *Physocarpus capitatus* (Pursh) Kuntze (Rosaceae) (Pacific Ninebark), a shrub native to the western United States, aggregated actin in cells and induced the formation of binucleated cells, a sign of strong cytokinesis-inhibitory activity (Figure 1). The active *P. capitatus* extract was fractionated by several rounds of reversed-phase and silica column chromatography,

followed by reversed-phase HPLC separation. Nineteen active fractions were examined by NMR and found to contain assorted cucurbitacins. Comparison of chemical shifts to literature values revealed cucurbitacin F (**1**)[7,8] as the most potent cucurbitacin from *P. capitatus*, and the known cucurbitacin 23,24-dihydrocucurbitacin F (**2**)[7,9] was also observed.

cucurbitacin F (**1**)   23,24-dihydrocucurbitacin F (**2**)

3: R = Ac R' = H
4: R = H   R' = Ac

Closer inspection of the double quantum-filtered COSY spectra of the less active fractions revealed two new cucurbitacins (**3** and **4**). A spin system connecting methine carbons C-15 (δ 3.98 in **3**, 4.66 in **4**), C-16 (δ 5.33 in **3**, 4.47 in **4**), and C-17 (δ 2.65 in **3**, 2.49 in **4**) revealed a site of oxidation at carbon C-15. HMBC correlations from protons H-16 of **3** (δ 5.33) and H-15 of **4** (δ 4.66) to acetate carbonyls at δ 170.8 and 171.2, respectively, suggested that the two cucurbitacins differ only in the site of acetylation. A NOESY correlation between protons H-15 (δ 3.98 in **3**; 4.66 in **4**) and H-16 (δ 5.33 in **3**, 4.47 in **4**) indicates that both hydroxyls are on the same face. Remaining NMR chemical shifts indicated that the structures are in all other ways identical to cucurbitacin F (Table 1).

Effects of cucurbitacins on actin have been reported in the literature,[10−13] and a recent study suggests that they may interact with actin directly.[14] Studies are ongoing to investigate the mechanism of action for this interesting family of compounds.

Experimental Section

General Experimental Procedures. ^{1}H NMR and ^{13}C NMR spectra were obtained on a Varian INOVA 600 MHz spectrometer with standard pulse sequences. CD_3OD was used as solvent. Offline processing was conducted using Mestre-C NMR software (Mestrelab Research, A Coruña, Spain; www.mestrec.com). ^{1}H and ^{13}C chemical shifts were

* Corresponding author. E-mail: jon_clardy@hms.harvard.edu.
† Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School.
‡ Department of Systems Biology, Harvard Medical School.
§ Dana-Farber Cancer Institute.

Table 1. NMR Chemical Shifts of Cucurbitacins (**1**–**4**) in CD$_3$OD (^{1}H 600 MHz; ^{13}C 100 MHz)

	1		2		3		4	
	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H	δ_C	δ_H
1	34.4	1.02, 1.80	34.4[a]	1.02[a], 1.80[a]	33.4	1.02, 1.78	33.4[a]	1.02[a], 1.78[a]
2	71.5	3.54	71.5[a]	3.54[a]	70.3	3.55	70.3[a]	3.55[a]
3	81.9	2.85	81.9[a]	2.85[a]	80.7	2.85	80.7[a]	2.85[a]
4	43.0		43.0[a]		42.0		42.0[a]	
5	142.5		142.5[a]		140.9		140.9[a]	
6	119.7	5.75	119.7[a]	5.74	118.9	5.72	118.9[a]	5.72[a]
7	24.6	1.97, 2.40	24.6[a]	1.97[a], 2.40[a]	22.1	2.32, 2.71	22.1[a]	2.32[a], 2.71[a]
8	44.2	1.93	44.2[a]	1.93[a]	43.1	2.11	43.2[a]	2.11[a]
9	49.6		49.6[a]		48.7		48.7[a]	
10	34.9	2.48	34.9[a]	2.48[a]	33.8	2.49	33.8[a]	2.49[a]
11	215.8		215.8[a]		214.0		214.0[a]	
12	49.7	2.55, 3.31	49.7[a]	2.55[a], 3.31[a]	48.4	2.57, 3.42	48.4[a]	2.58[a], 3.42[a]
13	48.8		48.9		47.5		47.5[a]	
14	51.8		51.7		49.5		48.4	
15	46.4	1.39, 1.84	46.4	1.38, 1.82	75.0	3.98	79.7	4.66
16	71.8	4.46	71.2	4.41	72.8	5.33	68.5	4.47
17	59.3	2.60	59.0	2.57	53.2	2.65	56.9	2.49
18	20.4	0.90	20.1	0.90	19.4	0.97	19.4[a]	0.96
19	20.3	1.07	20.3[a]	1.07[a]	18.9	1.09	18.9[a]	1.09[a]
20	79.6		80.5		78.5		78.5[a]	
21	25.2	1.38	25.3	1.38	23.3	1.38	23.3	1.38
22	204.7		216.9		202.8		203.3	
23	120.9	6.82	33.0	2.72, 2.85	119.4	6.80	119.2	6.80
24	155.0	6.97	37.9	1.71, 1.72	155.2	7.04	154.4	6.98
25	71.3		70.7		70.5		70.5	
26	29.1	1.32	29.1	1.19	27.9	1.32	27.9[a]	1.32[a]
27	29.1	1.33	29.1	1.19	28.1	1.34	28.1[a]	1.34[a]
28	22.1	0.96	22.1[a]	0.96[a]	20.9	0.97	20.9[a]	0.97[a]
29	25.2	1.17	25.2[a]	1.17[a]	24.0	1.16	24.0[a]	1.16[a]
30	28.9	1.30	28.9	1.30	11.6	1.20	12.8	1.31
31					170.8		171.2	
32					19.8	1.90	19.8	2.10

^{a} Overlapped signals.

Figure 1. Actin aggregates and cytokinesis failure resulting from cucurbitacin treatment. *Drosophila* Kc$_{167}$ cells were treated with an extract of *P. capitatus*, allowed to undergo a full cell cycle, fixed, and stained with TRITC-phalloidin to visualize actin (red) and Hoechst dye to visualize DNA (green).

referenced with the methanol solvent peaks at δ 3.31 and 49.05, respectively. LCMS data were obtained using a Micromass Platform LC-Z spectrometer, equipped with a Waters 2690 LC system and Waters 2690 photodiode array detector, and processed using MassLynx software (Waters Corporation, Milford, MA; www.waters.com). HPLC was carried out on an Agilent 1100 system equipped with diode array detector and operated with Chemstation software (Agilent Technolo-

gies). All HPLC separations were done using a Discovery HS-C18 column (Supelco, 250 × 10.0 mm, 5 mm particle size) with a 4 mL/min flow rate. Column chromatography was carried out on silica gel 60 (FisherChemicals, 230−400 mesh) and octadecyl-functionalized silica gel (Aldrich).

Plant Material. Approximately 18 g of an organic extract of *Physocarpus capitatus* (NPID N102479) was provided by Gordon Cragg in the Natural Products Branch of the National Cancer Institute. The plant material was collected in August 1997 in the Umpqua National Forest, Jackson County, Oregon (longitude: 123 005.88 W; latitude: 42 40.26 N). The plant material was identified by W. Hess, and a voucher specimen is on deposit at the Smithsonian Institute, U.S. National Herbarium in Washington, DC (specimen no. 0GDK0989). Extraction was performed according to the standard NCI protocol. (In brief, plant material was extracted with 1:1 dichloromethane/methanol followed by a wash with 100% methanol. The extract and methanol wash were combined prior to evaporation).

Isolation. The crude NCI extract (18 g) was dissolved in aqueous MeOH (90%) and partitioned against hexanes (700 mL × 3), then adjusted to 60% MeOH and extracted with CH$_2$Cl$_2$ (1000 mL × 3). The CH$_2$Cl$_2$ layer (4.5 g) was chromatographed on C18 silica gel, and five fractions eluted with a MeOH/H$_2$O step gradient. Fraction 2 (0.59 g) from this step was again chromatographed on C18 silica gel, this time eluting with 50% aqueous MeOH to give four fractions. Fractions 1 (412 mg) and 2 (231 mg) were combined and chromatographed on silica gel using a CH$_2$Cl$_2$/MeOH step gradient to give seven fractions. Fractions 4 (70 mg) and 5 (160 mg) were combined and subjected to RP-HPLC with an acetonitrile/H$_2$O gradient, yielding nine fractions. Finally, fraction 4 (53 mg) was separated into 11 more fractions by RP-HPLC with a MeOH/H$_2$O gradient. Fraction 4 (16.9 mg) from this last column contained a mixture of cucurbitacins **3** and **4**. Fraction 9 (2.4 mg) contained a mixture of 23,24-dihydrocucurbitacin F (**2**), cucurbitacin F (**1**), and a biphenyl, and fraction 10 (3.8 mg) contained pure cucurbitacin F (**1**).

Cucurbitacin F (1): Physical constants were identical to those reported in the literature;[7] ^{13}C and ^{1}H NMR spectroscopic data, see Table 1.

23,24-Dihydrocucurbitacin F (2). (characterized as a mixture with **1**): Physical constants were identical to those reported in the literature;[7] ^{13}C and ^{1}H NMR spectroscopic data, see Table 1.

Compound 3. (characterized as a 6:1 mixture with **4**): white solid; ^{13}C NMR (CD$_3$OD, δ) 214.0 (C-11), 202.8 (C-22), 170.8 (C-31), 155.2 (C-24), 140.9 (C-5), 119.4 (C-23), 118.9 (C-6), 80.7 (C-3), 78.5 (C-20), 75.0 (C-15), 72.8 (C-16), 70.5 (C-25), 70.3 (C-2), 53.2 (C-17), 49.5 (C-14), 48.7 (C-9), 48.4 (C-12), 47.5 (C-13), 43.1 (C-8), 42.0 (C-4), 33.8 (C-10), 33.4 (C-1), 28.1 (C-27), 27.9 (C-26), 24.0 (C-29), 23.3 (C-21), 22.1 (C-7), 20.9 (C-28), 19.8 (C-32), 19.4 (C-18), 18.9 (C-19), 11.6 (C-30); ^{1}H NMR (CD$_3$OD, δ) 7.04 (1H, d, J = 15.4 Hz, H-24), 6.80 (1H, d, J = 15.4 Hz, H-23), 5.72 (1H, dt, J = 6.2 Hz, J = 2.1 Hz, H-6), 5.33 (1H, t, J = 7.9 Hz, H-16), 3.98 (1H, d, J = 8.1 Hz, H-15), 3.55 (1H, ddd, J = 11.6 Hz, J = 9.4 Hz, J = 4.2 Hz, H-2), 3.42 (1H, d, J = 14.2 Hz, H-12a), 2.85 (1H, d, J = 9.4 Hz, H-3), 2.71 (1H, ddd, J = 19.1 Hz, J = 6.2 Hz, J = 1.7 Hz, H-7a), 2.65 (1H, d, J = 7.6 Hz, H-17), 2.57 (1H, d, J = 14.2 Hz, H-12b), 2.49 (1H, m, H-10), 2.32 (1H, m, H-7b), 2.11 (1H, m, H-8), 1.90 (3H, s, H-32), 1.78 (1H, dt, J = 12.3 Hz, J = 4.2 Hz, H-1a), 1.38 (3H, s, H-21), 1.34 (3H, s, H-27), 1.32 (3H, s, H-26), 1.20 (3H, s, H-30), 1.16 (3H, s, H-29), 1.09 (3H, s, H-19), 1.02 (1H, dd, J = 12.3 Hz, J = 11.6 Hz, H-1b), 0.97 (3H, s, H-18), 0.97 (3H, s, H-28); HRESIMS (*m/z*) [M + Na]$^+$ calcd for C$_{32}$H$_{48}$O$_9$ + Na, 599.3196; found, 599.3202.

Compound 4. (characterized as a 1:6 mixture with **3**): white solid; ^{13}C NMR (CD$_3$OD, δ): 214.0 (C-11), 203.3 (C-22), 171.2 (C-31), 154.4 (C-24), 140.9 (C-5), 119.2 (C-23), 118.9 (C-6), 80.7 (C-3), 79.7 (C-15), 78.5 (C-20), 70.5 (C-25), 70.3 (C-2), 68.5 (C-16), 56.9 (C-17), 48.7 (C-9), 48.4 (C-14), 48.4 (C-12), 47.5 (C-13), 43.2 (C-8), 42.0 (C-4), 33.8 (C-10), 33.4 (C-1), 28.1 (C-27), 27.9 (C-26), 24.0 (C-29), 23.3 (C-21), 22.1 (C-7), 20.9 (C-28), 19.8 (C-32), 19.4 (C-18), 18.9 (C-19), 12.8 (C-30); ^{1}H NMR (CD$_3$OD, δ) 6.98 (1H, d, J = 15.4 Hz, H-24), 6.80 (1H, d, J = 15.4 Hz, H-23), 5.72 (1H, dt, J = 6.2 Hz, J = 2.1 Hz, H-6), 4.66 (1H, d, J = 7.9 Hz, H-15), 4.47 (1H, t, J = 7.7 Hz, H-16), 3.55 (1H, ddd, J = 11.6 Hz, J = 9.4 Hz, J = 4.2 Hz, H-2), 3.42 (1H, d, J = 14.2 Hz, H-12a), 2.85 (1H, d, J = 9.4 Hz, H-3), 2.71 (1H, ddd, J = 19.1 Hz, J = 6.2 Hz, J = 1.7 Hz, H-7a), 2.58 (1H, d, J = 14.6 Hz, H-12b), 2.49 (1H, d, J = 7.6 Hz, H-17), 2.49 (1H, m, H-10), 2.32 (1H, m, H-7b), 2.11 (1H, m, H-8), 2.10 (3H, s, H-32), 1.78 (1H, dt, J = 12.3 Hz, J = 4.2 Hz, H-1a), 1.38 (3H, s, H-21), 1.34 (3H, s, H-27), 1.32 (3H, s, H-26), 1.31 (3H, s, H-30), 1.16 (3H, s, H-29), 1.09 (3H, s, H-19), 1.02 (1H, dd, J = 12.3 Hz, J = 11.6 Hz, H-1b), 0.97 (3H, s, H-28), 0.96 (3H, s, H-18). HRESIMS (*m/z*) [M + Na]$^+$ calcd for C$_{32}$H$_{48}$O$_9$ + Na, 599.3196; found, 599.3202.

Supporting Information Available: NMR (1D and 2D) spectra of compounds **1**−**4**. This material is available free of charge via the Internet at http://pubs.acs.org.

References and Notes

(1) Hung, D. T.; Jamison, T. F.; Schreiber, S. L. *Chem. Biol.* **1996**, *3*, 623–639.
(2) Newman, D. J.; Cragg, G. M.; Holbeck, S.; Sausville, E. A. *Curr. Cancer Drug Targets* **2002**, *2*, 279–308.
(3) Cragg, G. M.; Boyd, M. R.; Christini, M. A.; Kneller, R.; Mays, T. D.; Mazan, K. D.; Newman, D. J.; Sausville, E. A. In *Phytochemical Diversity: A Source of New Industrial Products*; Wrigley, S. K., Hays, M. A., Chrystal, E. J., Thomas, R., Eds.; Royal Society of Chemistry: Cambridge, 1997; pp 1−29.
(4) For a review of the history of small molecules that target the cytoskeleton, see: Peterson, J. R.; Mitchison, T. J. *Chem. Biol.* **2002**, *9*, 1275–1285.
(5) Eggert, U. S.; Kiger, A. A.; Richter, C.; Perlman, Z. E.; Perrimon, N.; Mitchison, T. J.; Field, C. M. *PLoS Biol.* **2004**, *2*, e379.
(6) Hertzberg, R. P. *Curr. Opin. Biotechnol.* **1993**, *4*, 80–84.
(7) Fang, X.; Phoebe, C. H.; Pezzuto, J. M.; Fong, H. H. S.; Farnsworth, N. R. *J. Nat. Prod.* **1984**, *47*, 988–993.
(8) Rehm, S.; Enslin, P. A.; Meeuse, A. D.; Wessels, J. H. *J. Sci. Food Agric.* **1957**, *8*, 679–686.
(9) Bittner, M.; Poyser, K. A.; Poyser, J. P.; Silva, M. *Phytochemistry* **1973**, *12*, 1427–1431.
(10) Musza, L. L.; Speight, P.; McElhiney, S.; Barrow, C. J.; Gillum, A. M.; Cooper, R.; Killar, L. M. *J. Nat. Prod.* **1994**, *57*, 1498–1502.
(11) Duncan, K. L.; Duncan, M. D.; Alley, M. C.; Sausville, E. A. *Biochem. Pharmacol.* **1996**, *52*, 1553–1560.
(12) Duncan, M. D.; Duncan, K. L. *J. Surg. Res.* **1997**, *69*, 55–60.
(13) Graness, A.; Poli, V.; Goppelt-Struebe, M. *Biochem. Pharmacol.* **2006**, *72*, 32–41.
(14) Momma, K.; Masuzawa, Y.; Nakai, N.; Chujo, M.; Murakami, A; Kioka, N.; Kiyama, Y.; Akita, T.; Nagao, M. *Cytotechnology* **2008**, *56*, 33–39.

NP8005259